Navigation Links
Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research

e following location:

http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey ={188066EA-1D6A-4A42-A0B8-0E27B5DA8D33}&SKey={F80F5B70-96B7-4FF9-A8FF-96 3E225CBA20}&MKey={E3F4019C-0A43-4514-8F66-B86DC90CD935}&AKey={728BCE9C-1 21B-46B9-A8EE-DC51FDFC6C15} <http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKe y=%7b188066EA-1D6A-4A42-A0B8-0E27B5DA8D33%7d&SKey=%7bF80F5B70-96B7-4FF9- A8FF-963E225CBA20%7d&MKey=%7bE3F4019C-0A43-4514-8F66-B86DC90CD935%7d&AKe y=%7b728BCE9C-121B-46B9-A8EE-DC51FDFC6C15%7d>

About Santaris Pharma

Santaris Pharma is a clinical-stage biopharmaceutical company focused on developing a new class of RNAi drugs intended to switch off the expression of harmful genes. Called RNA Antagonists, these new drugs are being developed by Santaris and its corporate partners for the treatment of cancer and metabolic disorders. Created in May 2003 and backed by a broad group of leading international life science venture capital investors, Santaris Pharma completed a Euro 40m second round of equity financing in May 2006. In July 2006, the Company entered into a global partnership with Enzon Pharmaceuticals of New Jersey to co-develop and commercialise a series of Santaris RNA Antagonists for improving the treatment of cancer.

Santaris Pharma's RNA Antagonist drug pipeline is based on its unique Locked Nucleic Acid (LNA) technology. LNA drugs, with their high potency and biostability, have the potential to transform the field of RNAi medicines, making specific and effective gene silencing a reality in human medicine. If this potential is realised, even in part, it may be possible to design new drugs to treat the underlying genetic causes of disease rather than just the physical s
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:12/24/2014)... CHENGDU, China, Dec. 24, 2014 /PRNewswire/  -- Tianyin ... a pharmaceutical company that specializes in the patented ... and active pharmaceutical ingredients (API) released unaudited preliminary ... year 2015. Fiscal Year 2015 Ended ... was $9.7 million compared with $14.7 million in ...
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., the ... the proprietary Natural Killer (NK) cell-line platform, Neukoplast® ... Patrick Soon-Shiong , NantWorks founder, physician scientist ... agreement to purchase approximately $48 million of the ... the investment, he will be named Co-Chairman of ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
... Subjects with ALS, RICHMOND, Calif., Sept. 3 ... it has opened a Phase,2 clinical trial (SB-509-801) to ... degenerative motor-neuron disease for which there,are limited treatment options ... injectable formulation of a plasmid,encoding a zinc finger DNA-binding ...
... , - This Analysis Showed That Multaq(R) (Dronedarone) ... Atrial Fibrillation or Atrial Flutter,Already Adequately Treated by Antithrombotic ... the data from the ATHENA study,were presented today at ... Cardiology congress 2008, in Munich, Germany. Previous results,from the ...
Cached Medicine Technology:Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5
(Date:12/25/2014)... 2014 The microscopy market is ... to reach $5,756.0 million by 2019. Optical microscopy ... The electron microscopes product segment is expected to ... , Rising focus on nanotechnology, technological advancements, and ... microscopy market. , Get Full Copy of Report ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... The short film “Color of Honor” by young ... a true 9/11 hero, Welles Remy Crowther. It has been ... hours of Nuremberg International Short Film Festival and the 8th ... screenwriter and director Luciana Lagana plays the mother of ... husband, Gregory Graham - Graham plays a heroic ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... WASHINGTON, Jan. 11 The Executive Council of the International ... to oppose any health care reform legislation that is funded ... , "For decades, IAM members exchanged substantial wage increases for ... "Now, in a bizarre turn of events, their insurance premiums ...
... , DUBLIN, Calif., Jan. 11 ... today announced it received an additional over-the-counter (OTC) clearance ... for its flagship product, TRIA Laser Hair Removal System ... hair reduction, making it the first and only at-home ...
... 2010 - A new study by a researcher at ... moods impact the number of prescriptions, referrals and lab ... they spend talking with their patients. The findings of ... to Tests and Specialists: Associations with Physician Burnout and ...
... a more strongly evidence-based approach to medicine would help ... nations and improve quality, access, efficiency, equity and healthy ... International Journal of Public Policy this month. ... Public Health, at the University of North Florida, in ...
... safe practices only about half the time, study finds, ... made for kids are getting better at portraying safety ... they,re still missing the mark about half the time. ... been tracking injury-prevention practices in movies since 1995. The ...
... , CHICAGO, Jan. 11 ... Stimulus Program , making it safe and easy for physicians ... qualify for significant federal incentives. , (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ... a guarantee that the Allscripts EHR they select will meet ...
Cached Medicine News:Health News:Machinists Union Leaders Vote to Oppose Health Benefits Tax 2Health News:FDA Grants Permanent Hair Reduction Labeling for TRIA Laser Hair Removal System 2Health News:Considering the evidence in health care 2Health News:Seat Belts, Bike Helmets Go Unused in Movies Aimed at Kids 2Health News:Seat Belts, Bike Helmets Go Unused in Movies Aimed at Kids 3Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 2Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 3Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 4Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 5Health News:Allscripts Announces Rapid Implementation, 'Meaningful Use' Guarantee, and Financing Programs for Electronic Health Records 6
Tilt Adapter for the 8000 Sliding Microtome to allow for orientation of the specimen....
... Microtome has a look that is revolutionary, a ... functions and capabilities that will please the most ... experience and knowledge but still breaking new ground ... will be the answer to many of your ...
Clock oil, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Medicine Products: